Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
Fiche publication
Date publication
mai 2017
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BIBEAU Frédéric
Tous les auteurs :
Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile JF, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, Ychou M, Martineau P
Lien Pubmed
Résumé
Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab. The aim of this study was to evaluate if recently identified molecular subtypes of colon cancer are associated with response of metastatic patients to first-line therapy.
Mots clés
Bevacizumab, Cetuximab, Colorectal neoplasms, FOLFIRI protocol, Folfox protocol, Gene expression profiling
Référence
Eur J Cancer. 2017 05;76:68-75